APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:500-1:3000 |
1:100-1:1000 |
Not tested in other applications.
Calculated MW
Positive Control
293T (0.5 μM doxorubicin for 24 hr)
Predict Reactivity
Rabbit, Bovine, Guinea pig, Rhesus Monkey(>80% identity)
PROPERTIES
Form
Liquid
Buffer
1XPBS (pH7), 1% BSA, 20% Glycerol
Preservative
0.025% ProClin 300
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.24 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Carrier-protein conjugated synthetic peptide surrounding phospho Ser15 of human p53. The exact sequence is proprietary.
Purification
Purified by antigen-affinity chromatography.
Conjugation
Unconjugated
RRID
AB_2886801
Note
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET
Synonyms
tumor protein p53 , BCC7 , BMFS5 , LFS1 , P53 , TRP53
Cellular Localization
Cytoplasm , Nucleus , Endoplasmic reticulum
Background
This gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity. [provided by RefSeq]
Database
Research Area
DATA IMAGES
|
GTX132995 WB Image
Untreated (–) and treated (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with p53 (phospho Ser15) antibody (GTX132995) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
|
|
GTX132995 ICC/IF Image
p53 (phospho Ser15) antibody detects p53 (phospho Ser15) protein at nucleus by immunofluorescent analysis. Sample: Mock and treated 293T cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: p53 (phospho Ser15) protein stained by p53 (phospho Ser15) antibody (GTX132995) diluted at 1:2000. Blue: Hoechst 33342 staining. Scale bar = 10 μm.
|
REFERENCE
REVIEW
p53 (phospho Ser15) antibody
Cat. No. GTX132995
Rating
|
|
( Average 5 based on 1 users reviews)
|
Application
Western Blot(WB)
|
|
( Average 5 based on 1 users reviews)
|
Date :
Anonymous submitted on 01-Aug-2018
Application Tested :
WB
Sample Species :
Hu
Sample :
A549 cells
Amount used :
40 μg
Blocking :
0.5% BSA, 25°C, 2Hr
Primary Antibody :
1:1000, 4°C, 16Hr